SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Lowered by Wall Street Zen

SAB Biotherapeutics (NASDAQ:SABS) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other brokerages have also recently weighed in on SABS. Chardan Capital boosted their price target on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. HC Wainwright lowered their price objective on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, March 10th. Guggenheim started coverage on shares of SAB Biotherapeutics in a research note on Friday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a report on Monday, December 29th. Finally, UBS Group started coverage on shares of SAB Biotherapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $7.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

SAB Biotherapeutics Stock Performance

NASDAQ SABS opened at $4.15 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 9.46. SAB Biotherapeutics has a 1-year low of $1.00 and a 1-year high of $6.60. The business has a 50 day simple moving average of $4.02 and a two-hundred day simple moving average of $3.38. The stock has a market capitalization of $211.44 million, a PE ratio of -1.79 and a beta of 0.59.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.30). On average, research analysts predict that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC bought a new stake in shares of SAB Biotherapeutics during the third quarter worth $30,000. Dimensional Fund Advisors LP bought a new position in shares of SAB Biotherapeutics in the third quarter worth about $32,000. State of Wyoming bought a new position in shares of SAB Biotherapeutics in the fourth quarter worth about $34,000. Virtu Financial LLC purchased a new position in SAB Biotherapeutics in the 3rd quarter worth about $40,000. Finally, State Street Corp purchased a new position in SAB Biotherapeutics in the 4th quarter worth about $49,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.